Financials data is unavailable for this security.
View more
Year on year Astrazeneca Pharma India Ltd grew revenues 29.17% from 10.03bn to 12.96bn while net income improved 62.66% from 992.90m to 1.62bn.
| Gross margin | 48.51% |
|---|---|
| Net profit margin | 6.91% |
| Operating margin | 7.14% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Astrazeneca Pharma India Ltd did not generate a significant amount of cash. However, the company earned 278.70m from its operations for a Cash Flow Margin of 2.15%. In addition the company generated 217.40m cash from investing, though they paid out 443.80m more in financing than they received.
| Cash flow per share | 44.38 |
|---|---|
| Price/Cash flow per share | 163.56 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 50.00% and 62.66%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.32% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 62.59% |
| EPS growth(5 years) | 24.29 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -27.92 |
More ▼
